Read Marks & Clerks AI Report 2025 here.
Continued growth and ongoing mainstream adoption: AI patent publications at the EPO hit an all-time high in 2024, demonstrating the sustained, record-level investment and output in European AI development.
A tale of two innovation races: While the US and South Korea dominate per capita AI patent filings at the EPO - leaving Japan and Europe behind in a widening innovation gap - Japan has surged ahead in quantum AI, overtaking even the US in per capita QAI publications.
Allowance rate discrepancy: The allowance rate for Quantum AI applications at…
Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).
In his role at NRG, Paul will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026. NRG5051 is an oral, CNS-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP) acting via a novel mechanism of action (MoA). Inhibition of the mPTP…
We are pleased to share that o2h Discovery has been recognised as the ‘Best Industry Support Partner of the Year’ at the OBN Awards 2025. This achievement reflects the dedication of our exceptional teams and the strong, collaborative partnerships we have built with various innovative biotech and pharma organisations worldwide. This award follows our 2023 ‘Most Impactful CRO Award’ and holds special significance for us. It also showcases the steady progress we’ve made in enabling partners to advance their discovery programmes, strengthened by long-standing relationships and shared…
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing.
Through this partnership, customers will have access to integrated drug substance and drug product development,…
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainabilityOXFORD, UK and PORTLAND, ME – 25 November 2025 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced a collaboration to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting insights will potentially underpin a payor-facing test to…
24 November 2025, Paris, France / Biocair, an established global leader in life science logistics, today announced the relocation of its Paris facility to a new, substantially larger premises strategically positioned within the Paris-Charles de Gaulle airport cargo zone. This move strengthens Biocair’s presence in the geographical and logistical center of one of Europe’s major transport hubs.
The establishment of the new facility is a critical step in Biocair’s long-term strategy for the French market. The new location provides direct airport proximity, which will improve operational…
Edinburgh and Cambridge, UK, 25 November 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.
Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology.
There is clear…
Creative Biolabs is rewriting the methods scientists use to develop binders and antibodies in the changing environment of therapeutic discovery. The company, which has a set of advanced platforms, is, therefore, a partner that many researchers can hardly do without as they go deeper into the most challenging molecular frontiers.From membrane proteins and post-translational modifications to elusive haptens and idiotypes, Creative Biolabs offers a rare combination of scientific depth and operational agility. "We don’t just screen—we engineer precision," noted one senior scientist at Creative…
Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Widely cited in recent published papers1, 2, 3, 4 - Detachin™ is proven to quickly deliver gentle detachment of a wide variety of adherent cells, including primary cell types and delicate culture systems, from any tissue culture plasticware. These papers involving primary immune cells, patient-derived cancer models, engineered mammalian lines and high-throughput screening systems, provide further…
Highly accomplished senior real estate executive leader and investment professional, Andy Creighton, joins Howard Group
Cambridge, 18th November 2025: Leading regional property investor and developer Howard Group, is delighted to announce the appointment of Andy Creighton as Group Property Director.
In his new role, Andy will be responsible for overseeing Howard Group’s property activities, including its investment, development and asset management functions. He will also be appointed to the Board of Directors and join the Executive Team.
Andy brings a long and…